Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesco De Cesaris

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
Internal and Emergency Medicine|June 12, 2021
COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case reportLuigi Francesco Iannone, Pierangelo Geppetti, Alberto Chiarugi, et al.
Neuroscience Letters|December 3, 2021
The role of TRP ion channels in migraine and headacheLuigi Francesco Iannone, Francesco De Logu, Pierangelo Geppetti, et al.
The Journal of Headache and Pain|January 30, 2017
P010. OnabotulinumtoxinA for treatment of chronic migraine: results after 1 year of treatmentEleonora Rossi, Chiara Lupi, Silvia Benemei, et al.
European Journal of Pharmacology|February 23, 2025
The anti-CGRP mAb Fremanezumab reverts the anti-inflammatory effects of CGRP in vitro but does not alter disease evolution in a mouse model of progressive multiple sclerosisAlessandra Pistolesi, Alice Molli, Francesco De Cesaris, et al.
Handbook of Experimental Pharmacology|August 6, 2009
MigraineSilvia Benemei, Paola Nicoletti, Jay G Capone, et al.
Internal and Emergency Medicine|June 21, 2008
Defining neuralgiform headache with ipsilateral autonomic symptoms: case report in a headache centerFrancesco De Cesaris, Marcello Fanciullacci, Umberto Pietrini, et al.
Annals of Clinical and Translational Neurology|April 17, 2025
Patients' Global Impression of Change (PGIC) Score Compared to Monthly Migraine Days to Evaluate Treatment Persistence With Anti-CGRP Monoclonal AntibodiesMarina Romozzi, Catello Vollono, Paolo Calabresi, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|April 27, 2010
Transient receptor potential channels as novel drug targets in respiratory diseasesRomina Nassini, Serena Materazzi, Gaetano De Siena, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 26, 2010
Migraine modelsSilvia Benemei, Francesco De Cesaris, Paola Nicoletti, et al.
The Journal of Headache and Pain|August 15, 2013
TRPA1 and other TRP channels in migraineSilvia Benemei, Francesco De Cesaris, Camilla Fusi, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
Internal and Emergency Medicine|June 12, 2021
COVID-19 pneumonia during long-term migraine prophylaxis with fremanezumab: a case reportLuigi Francesco Iannone, Pierangelo Geppetti, Alberto Chiarugi, et al.
Neuroscience Letters|December 3, 2021
The role of TRP ion channels in migraine and headacheLuigi Francesco Iannone, Francesco De Logu, Pierangelo Geppetti, et al.
The Journal of Headache and Pain|January 30, 2017
P010. OnabotulinumtoxinA for treatment of chronic migraine: results after 1 year of treatmentEleonora Rossi, Chiara Lupi, Silvia Benemei, et al.
European Journal of Pharmacology|February 23, 2025
The anti-CGRP mAb Fremanezumab reverts the anti-inflammatory effects of CGRP in vitro but does not alter disease evolution in a mouse model of progressive multiple sclerosisAlessandra Pistolesi, Alice Molli, Francesco De Cesaris, et al.
Handbook of Experimental Pharmacology|August 6, 2009
MigraineSilvia Benemei, Paola Nicoletti, Jay G Capone, et al.
Internal and Emergency Medicine|June 21, 2008
Defining neuralgiform headache with ipsilateral autonomic symptoms: case report in a headache centerFrancesco De Cesaris, Marcello Fanciullacci, Umberto Pietrini, et al.
Annals of Clinical and Translational Neurology|April 17, 2025
Patients' Global Impression of Change (PGIC) Score Compared to Monthly Migraine Days to Evaluate Treatment Persistence With Anti-CGRP Monoclonal AntibodiesMarina Romozzi, Catello Vollono, Paolo Calabresi, et al.
Current Opinion in Investigational Drugs (London, England : 2000)|April 27, 2010
Transient receptor potential channels as novel drug targets in respiratory diseasesRomina Nassini, Serena Materazzi, Gaetano De Siena, et al.
Methods in Molecular Biology (Clifton, N.J.)|March 26, 2010
Migraine modelsSilvia Benemei, Francesco De Cesaris, Paola Nicoletti, et al.
The Journal of Headache and Pain|August 15, 2013
TRPA1 and other TRP channels in migraineSilvia Benemei, Francesco De Cesaris, Camilla Fusi, et al.
Pageof 7